Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study

Overview of attention for article published in Neurotherapeutics, May 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 37 Dimensions

Readers on

mendeley: 81 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 7,153 followers.

Casasnovas, C., Pujol, A., et. al. (2019). Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study. Neurotherapeutics, 16(4), 1167-1182. https://t.co/1uqbGUcKpA

28 Feb 2021

Reply Repost Favourite

Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy (AMN): a Phase II Pilot Study https://t.co/1OeZFl8c6U

12 Jun 2019

Reply Repost Favourite

RT @craibiologia: 🔬 "Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot S…

16 May 2019

Reply Repost Favourite

🔬 "Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study", Francesc Villarroya, Aurora Pujol, Carlos Casasnovas et al. #RecercaCRAIBiologiaUB 👉Article: https://t.co/twFDGAEzvF (open acce

16 May 2019

Reply Repost Favourite